Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytokinetics, Incorporated - Common Stock
(NQ:
CYTK
)
54.76
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytokinetics, Incorporated - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Cytokinetics, Incorporated (CYTK) Q2 2021 Earnings Call Transcript
August 06, 2021
CYTK earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Cytokinetics: Q2 Earnings Insights
August 05, 2021
Shares of Cytokinetics (NASDAQ:CYTK) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 26.47% over the past...
Via
Benzinga
Cell Analysis Instruments Provider Cytek Biosciences Kick Starts Trading After Pricing IPO At $17
July 23, 2021
Cytek Biosciences Inc (NASDAQ: CTKB) shares started trading today after its initial public offering was priced to raise about $200 million for the cell-analysis Company....
Via
Benzinga
Topics
Initial Public Offering
Why Cytokinetics (CYTK) Shares Are Trading Higher Today?
July 20, 2021
Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
July 20, 2021
Citigroup boosted International Business Machines Corporation (NYSE:
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
54 Biggest Movers From Yesterday
July 20, 2021
Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million single purchase order from its lead silicon...
Via
Benzinga
Why Is Cytokinetics Inc. (NASDAQ: CYTK) The Best Stock of the Day?
July 19, 2021
Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve...
Via
Benzinga
Dow on Pace for Worst Day of 2021 as Covid-19 Fears Weigh
July 19, 2021
The Dow Jones Industrial Average is down more than 760 points at midday and is eyeing its worst daily drop for 2021.
Via
Talk Markets
Topics
Stocks
Here's Why Cytokinetics Is Rocketing Higher Today
July 19, 2021
The company's new heart drug candidate produced encouraging clinical trial results.
Via
The Motley Fool
Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher
July 19, 2021
Midway through trading Monday, the Dow traded down 2.28% to 33,896.40 while the NASDAQ fell 1.31% to 14,238.93. The S&P also fell, dropping 1.74% to 4,251.79. The U.S. has the...
Via
Benzinga
Topics
Stocks
30 Stocks Moving In Monday's Mid-Day Session
July 19, 2021
Gainers Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM. Aehr Test Systems (...
Via
Benzinga
CYTK Stock Flies High on Exciting Drug Trial Results
July 19, 2021
CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment.
Via
InvestorPlace
How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout
July 19, 2021
Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates
July 19, 2021
Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38. The U.S....
Via
Benzinga
Topics
Stocks
Stocks That Hit 52-Week Highs On Monday
July 19, 2021
On Monday morning, 20 companies achieved new highs for the year. Areas of Significance: The largest company by market cap to break to a new 52-week high was PepsiCo...
Via
Benzinga
Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate
July 19, 2021
Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 19, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2...
Via
Benzinga
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
May 17, 2021
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart...
Via
Benzinga
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
May 07, 2021
CYTK earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
May 03, 2021
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...
Via
Benzinga
Topics
Regulatory Compliance
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.